TD Private Client Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.7K | Sell |
108
-19
| -15% | -$9.98K | ﹤0.01% | 825 |
|
|
2025
Q1 | $80.5K | Sell |
127
-44
| -26% | -$27.9K | ﹤0.01% | 732 |
|
|
2024
Q4 | $122K | Buy |
171
+15
| +10% | +$10.7K | ﹤0.01% | 686 |
|
|
2024
Q3 | $164K | Buy |
156
+7
| +5% | +$7.36K | ﹤0.01% | 644 |
|
|
2024
Q2 | $157K | Sell |
149
-8
| -5% | -$8.41K | ﹤0.01% | 611 |
|
|
2024
Q1 | $151K | Buy |
157
+20
| +15% | +$19.3K | 0.01% | 630 |
|
|
2023
Q4 | $120K | Buy |
137
+5
| +4% | +$4.39K | ﹤0.01% | 648 |
|
|
2023
Q3 | $109K | Sell |
132
-4
| -3% | -$3.29K | ﹤0.01% | 633 |
|
|
2023
Q2 | $97.7K | Sell |
136
-10
| -7% | -$7.19K | ﹤0.01% | 666 |
|
|
2023
Q1 | $120K | Buy |
146
+4
| +3% | +$3.29K | 0.01% | 621 |
|
|
2022
Q4 | $102K | Sell |
142
-7
| -5% | -$5.05K | ﹤0.01% | 624 |
|
|
2022
Q3 | $103K | Buy |
149
+33
| +28% | +$22.7K | 0.01% | 609 |
|
|
2022
Q2 | $68.6K | Sell |
116
-41
| -26% | -$24.2K | ﹤0.01% | 667 |
|
|
2022
Q1 | $110K | Buy |
157
+23
| +17% | +$16.1K | ﹤0.01% | 625 |
|
|
2021
Q4 | $84.6K | Buy |
134
+38
| +40% | +$24K | ﹤0.01% | 664 |
|
|
2021
Q3 | $58.1K | Sell |
96
-186
| -66% | -$113K | ﹤0.01% | 723 |
|
|
2021
Q2 | $158K | Buy |
282
+32
| +13% | +$17.9K | 0.01% | 555 |
|
|
2021
Q1 | $118K | Buy |
250
+83
| +50% | +$39.3K | 0.01% | 576 |
|
|
2020
Q4 | $80.7K | Sell |
167
-39
| -19% | -$18.8K | ﹤0.01% | 586 |
|
|
2020
Q3 | $115K | Sell |
206
-25
| -11% | -$14K | 0.01% | 514 |
|
|
2020
Q2 | $144K | Sell |
231
-18
| -7% | -$11.2K | 0.01% | 482 |
|
|
2020
Q1 | $122K | Buy |
249
+149
| +149% | +$72.8K | 0.01% | 473 |
|
|
2019
Q4 | $37.5K | Buy |
+100
| New | +$37.5K | ﹤0.01% | 643 |
|